GSK SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats
GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.
Top strength: Scale in vaccines. Primary risk: US pricing and vaccine policy.
- What are GSK's strengths?
- The main strengths in this analysis are: Scale in vaccines; Growing Specialty Medicines.
- What are GSK's weaknesses?
- The main weaknesses in this analysis are: Reliance on dolutegravir; Pipeline write-downs.
SWOT Analysis: GSK plc
Strengths
- Vaccines generated ~$12.1 billion (£9.2 billion) in 2025, led by Shingrix (~$4.75 billion (£3.6 billion)) and meningitis vaccines (~$2.11 billion (£1.6 billion)), backed by large biological manufacturing capacity and the AS01 adjuvant system.
- Specialty Medicines grew 17% to ~$17.8 billion (£13.5 billion) in 2025 and 14% in Q2 2026, with oncology up 43% in 2025.
Weaknesses
- HIV sales of ~$10.2 billion (£7.7 billion) rely heavily on dolutegravir-based regimens, which lose exclusivity between 2028 and 2030.
- The 2026 decision to stop camlipixant, acquired with Bellus Health in 2023, led to about $1.72 billion (£1.3 billion) of impairments in Q2 2026.
Opportunities
- Nuvalent's lung-cancer drugs, efimosfermin for steatotic liver disease and bepirovirsen for hepatitis B could add new revenue streams, supporting the target of more than $52.8 billion (£40 billion) in sales by 2031.
- The highly successful launch of Arexvy (the world's first RSV vaccine) opens a massive, multi-billion dollar adult immunization market, directly combatting Pfizer's rival vaccine.
Threats
- US drug-pricing reforms, tariffs and changes to vaccine recommendations can quickly reduce demand, as shown by the Arexvy slowdown in 2024-2025.
- Despite winning several initial court battles, GSK remains severely exposed to massive, multi-billion dollar class-action lawsuits alleging its heartburn drug Zantac causes cancer.
GSK SWOT Analysis FAQ
What are the core competitive strengths of GSK plc?
GSK's strengths include high-quality vaccine development and adjuvant technology (Shingrix, Arexvy), market leadership in HIV through ViiV Healthcare, strong commercial execution in global respiratory medicines (Trelegy), substantial operating cash flows, and deep scientific pedigree in functional genomics.
What internal weaknesses or legacy challenges does GSK manage?
Weaknesses include historical exposure to Zantac (ranitidine) product liability litigation settlements, historical pipeline clinical setbacks in early-stage oncology, and the need to continually replace mature General Medicines revenues.
What external threats challenge GSK's market leadership?
Threats include intense competition in adult RSV vaccines from Pfizer and Moderna, generic competition against older HIV regimens, regulatory drug pricing reforms (such as US Medicare Part D redesign and price negotiations), and vaccine hesitancy in select markets.
How does GSK's proprietary adjuvant technology create an enduring competitive barrier?
GSK's proprietary lipid and saponin-based adjuvant systems stimulate strong, long-lasting T-cell and antibody responses in aging immune systems. Because adjuvants are difficult to replicate, competitors cannot easily produce biosimilar vaccines.
Why is ViiV Healthcare's two-drug HIV regimen a commercial breakthrough?
Traditional HIV therapy required three or four daily antiretroviral drugs. ViiV proved that two-drug regimens (like Dovato) maintain complete viral suppression while reducing cumulative lifetime drug exposure, organ toxicity, and treatment costs for patients.
What risks are associated with vaccine clinical trial execution and regulatory filings?
Vaccine clinical trials require tens of thousands of healthy volunteers across global seasonal epidemiological waves. Unpredictable viral circulation, clinical endpoint misses, or rare adverse immunologic reactions can cause regulatory delays.
What is the biggest threat to GSK?
The absolute biggest existential threat is mass litigation. GSK is currently fighting massive, highly damaging lawsuits regarding Zantac (a heartburn medication they originally developed), which plaintiffs allege contained a cancer-causing chemical. If global courts rule against them, it could cost GSK massive billions in legal settlements.